Joel Eisner Ph.D.

Associate Principal

Dr. Eisner is an Associate Principal of Cato BioVentures focusing on our relationships with early-stage life science companies. He also serves as an Integrated Drug Development Scientist of Cato Research, and as Vice President, Corporate Development of Hemodynamic Therapeutics, a portfolio company. Dr. Eisner was Vice President, Corporate Development of Durham Pharmaceuticals Ltd. until its merger into Echo Therapeutics, Inc. (OTCBB: ECTE). Dr. Eisner is an Affiliate Scientist at the National Primate Research Center, University of Wisconsin-Madison. Prior to joining Cato BioVentures, he was a Clinical Operations Manager at Northwestern University Medical School and Brigham and Women’s Hospital. Prior to that he served as a Clinical Research Scientist for Insmed, Inc. (NASDAQ: INSM). Dr. Eisner has 12 years’ research experience in the field of endocrinology and reproductive physiology, and his areas of expertise include obesity, reproductive endocrinology, lipid abnormalities, diabetes, women’s health, and infertility. He has 10 years’ clinical research experience in both academic and pharmaceutical settings. Dr. Eisner is a member of the Endocrine Society.